Measured Wealth Private Client Group’s Citius Pharmaceuticals CTXR Stock Holding History

Measured Wealth Private Client Group’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-400	Closed	-$5.84K	–	185
2024 Q2	$5.84K	Hold	400	–	–	﹤0.01%	186
2024 Q1	$8.97K	Hold	400	–	–	﹤0.01%	185
2023 Q4	$7.57K	Hold	400	–	–	﹤0.01%	176
2023 Q3	$6.84K	Buy	+400	New	+$9.51K	﹤0.01%	166

Other funds holding CTXR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CCC

Chelsea Counsel Company Los Angeles, California $225M AUM 45.99% 1-Year Est. Return

Measured Wealth Private Client Group's CTXR Position: Q3 2024 in Review

Measured Wealth Private Client Group sold out of Citius Pharmaceuticals (CTXR) in Q3 2024, closing a stake of 400 shares — an estimated $5.84K sold.

Measured Wealth Private Client Group first reported a position in CTXR in Q3 2023 and held it in 4 quarters. The position peaked at $8.97K in Q1 2024. 57 funds tracked by Wall St. Rank hold CTXR as of Q3 2024.

Measured Wealth Private Client Group reported no remaining Citius Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Measured Wealth Private Client Group sold 400 Citius Pharmaceuticals shares in Q3 2024, an estimated $5.84K.
Measured Wealth Private Client Group first reported a position in Citius Pharmaceuticals in Q3 2023 and held it in 4 quarters.
Measured Wealth Private Client Group's Citius Pharmaceuticals position peaked at $8.97K in Q1 2024.
57 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2024.

Based on Measured Wealth Private Client Group's 13F filing for Q3 2024, filed 28 Oct 2024.